Canadian mouse study shows hormone associated with pregnancy may reverse MS
{{date|February 23, 2007}}
[[Image:Pregnant belly button.jpg |left|180px|thumb|Canadian researchers report a mechanism associated with pregnancy that may reverse symptoms of multiple sclerosis. <br/><small>''Photo credit'': Flickr user “Inferis”.</small>]]

Researchers with the [[w:University of Calgary|University of Calgary]] in [[Canada]] have found that [[w:Prolactin|prolactin]], a hormone produced during pregnancy, may reverse the progression of [[w:Multiple Sclerosis|multiple sclerosis]] (MS), according to a paper published this week in The Journal of Neuroscience.

The study, led by Drs. Samuel Weiss and V. Wee Yong of the Hotchkiss Brain Institute, compared virgin and pregnant mice with MS-like lesions introduced by [[w:Lysolecithin|lysolecithin]], a chemical which destroys the myelin sheaths around neurons.  They found the pregnant mice developed smaller lesions and fewer damaged neurons, and showed signs of repaired neurons.  They also found the pregnant mice had higher levels of cells called [[w:Oligodendrocytes|oligodendrocytes]], which create myelin and are able to repair some damaged neurons through [[w:remyelination|remyelination]]. Because prolactin regulates the levels of precursors of oligodendrocytes, the scientists hypothesized that prolactin levels were responsible for the differences in damage.  They also tested virgin mice given additional prolactin, and found results similar to pregnant mice.
{{missing image|Image:Monthly multiple sclerosis MRI.gif |right|280px|thumb|MS causes lesions on neurons in the brain and spinal cord.  These brain images show the progression of the lesions (white spots) on the brain over the course of a year. <br/><small>''Photo credit'': U.S. Brookhaven National Laboratory.</small>}}
Previous studies have shown that other hormones could reduce myelin damage, but this is the first study to show a mechanism to reverse myelin damage, and establish an empirical connection between that mechanism and pregnancy.  Dr. Weiss says, “It is thought that during pregnancy, women’s immune systems no longer destroyed the myelin.  However, no previous study has tested whether pregnancy actually results in the production of new myelin, which may lead to improvement of symptoms. "We're excited about this result because it suggests to us that prolactin has the potential to be used to enhance the production of new myelin.”

Dr. William McIlroy, national medical advisor for the Multiple Sclerosis Society of Canada, explains the significance of this study:  “The results of this study should be well received by people living with MS today.  It represents a new insight of how we might be able to reverse some of the effects of the disease and improve the quality of life for those who live under its influence.”  
{{missing image|Image:Prolactin.png|left|220px|thumb|Prolactin, shown here, is primarily responsible for stimulating lactation. <br/><small>Illustration by David S. Goodsell of The Scripps Research Institute</small>}}
Dr. Luanne Metz, director of the Calgary MS Clinic in the Department of Clinical Neurosciences, University of Calgary and Calgary Health Region, adds, “This discovery has the potential to take MS therapy a step further than current treatments that stabilize the disease in its early stages. By promoting repair, which is the goal of prolactin therapy, we have hope of actually improving symptoms in people with MS.”

Further animal studies need to be done to examine the possibility of side effects, such as lactation in men and non-pregnant women, as well as increased inflammation which could worsen the MS. Researchers believe human trials may begin within a few years.

Funding and support were provided by the [[w:Canadian Institutes of Health Research|Canadian Institutes of Health Research]] and the [[w:Multiple Sclerosis Society of Canada|Multiple Sclerosis Society of Canada]], the Alberta Heritage Foundation for Medical Research and the Stem Cell Network.

MS is an [[w:Autoimmune Diseases|autoimmune disease]] of the [[w:Central Nervous System|central nervous system]] where the body attacks the fatty [[w:Myelin|myelin]] which helps nerves carry electrical signals, causing muscle weakness and spasming which may lead to disability. MS affects approximately one of every 1000 people in North America, northern Europe and Australasia.

{{haveyoursay}}
== Sources ==
*{{Source-science|
 |authors= Christopher Gregg, Viktor Shikar, Peter Larsen, Gloria Mak, Andrew Chojnacki, V. Wee Yong, and Samuel Weiss
 |url= http://www.jneurosci.org/cgi/content/full/27/8/1812
 |title= Myelination and Remyelination in the Pregnant Mouse
 |journal=The Journal of Neuroscience
 |pubyear=2007
 |edition=27(8)
 |pagenumbers=1812-1823
 |database1url= http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&list_uids=17314279&dopt=Abstract
 |database1=PubMed
 |database2url=
 |database2=
 }}
*{{source|url= http://www.jneurosci.org/cgi/content/full/27/8/i
|title= This Week in The Journal
|author=
|pub=The Journal of Neuroscience
|date=February 21, 2007 }}
*{{source|url= http://www.ucalgary.ca/news/feb2007/ms-hormone/
|title= Pregnancy Hormone Key To Repairing Nerve Cell Damage
|author=
|pub=University of Calgary
|date=February 20, 2007 }}
*{{source|url= http://www.newscientist.com/channel/health/dn11224-pregnancy-hormone-reverses-ms-damage.html
|title= Pregnancy hormone reverses MS damage
|author=Roxanne Khamsi
|pub=New Scientist
|date=February 21, 2007 }}

{{publish}}
{{archive}}
[[Category:Health]]
[[Category:Science and technology]]
[[Category:Canada]]
[[Category:Biotechnology]]
[[Category:Biology]]
[[Category:University of Calgary]]
Canadian researchers report a mechanism associated with pregnancy that may reverse symptoms of multiple sclerosis. Photo credit: Flickr user “Inferis”.

Researchers with the University of Calgary in Canada have found that prolactin, a hormone produced during pregnancy, may reverse the progression of multiple sclerosis (MS), according to a paper published this week in The Journal of Neuroscience.

The study, led by Drs. Samuel Weiss and V. Wee Yong of the Hotchkiss Brain Institute, compared virgin and pregnant mice with MS-like lesions introduced by lysolecithin, a chemical which destroys the myelin sheaths around neurons.  They found the pregnant mice developed smaller lesions and fewer damaged neurons, and showed signs of repaired neurons.  They also found the pregnant mice had higher levels of cells called oligodendrocytes, which create myelin and are able to repair some damaged neurons through remyelination. Because prolactin regulates the levels of precursors of oligodendrocytes, the scientists hypothesized that prolactin levels were responsible for the differences in damage.  They also tested virgin mice given additional prolactin, and found results similar to pregnant mice.

Previous studies have shown that other hormones could reduce myelin damage, but this is the first study to show a mechanism to reverse myelin damage, and establish an empirical connection between that mechanism and pregnancy.  Dr. Weiss says, “It is thought that during pregnancy, women’s immune systems no longer destroyed the myelin.  However, no previous study has tested whether pregnancy actually results in the production of new myelin, which may lead to improvement of symptoms. "We're excited about this result because it suggests to us that prolactin has the potential to be used to enhance the production of new myelin.”

Dr. William McIlroy, national medical advisor for the Multiple Sclerosis Society of Canada, explains the significance of this study:  “The results of this study should be well received by people living with MS today.  It represents a new insight of how we might be able to reverse some of the effects of the disease and improve the quality of life for those who live under its influence.”  

Dr. Luanne Metz, director of the Calgary MS Clinic in the Department of Clinical Neurosciences, University of Calgary and Calgary Health Region, adds, “This discovery has the potential to take MS therapy a step further than current treatments that stabilize the disease in its early stages. By promoting repair, which is the goal of prolactin therapy, we have hope of actually improving symptoms in people with MS.”

Further animal studies need to be done to examine the possibility of side effects, such as lactation in men and non-pregnant women, as well as increased inflammation which could worsen the MS. Researchers believe human trials may begin within a few years.

Funding and support were provided by the Canadian Institutes of Health Research and the Multiple Sclerosis Society of Canada, the Alberta Heritage Foundation for Medical Research and the Stem Cell Network.

MS is an autoimmune disease of the central nervous system where the body attacks the fatty myelin which helps nerves carry electrical signals, causing muscle weakness and spasming which may lead to disability. MS affects approximately one of every 1000 people in North America, northern Europe and Australasia.
Health Science and technology Canada Biotechnology Biology University of Calgary